Biosimilars: FDA offers rationale for dropping interchangeability designations
Regulatory NewsJoanne S. Eglovitch
Advertising, Promotion and LabelingBiologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchAdvertising, Promotion and LabelingBiologics/ biosimilars/ vaccinesBiotechnologyNorth AmericaRegulatory Intelligence/Policy